I-Mab (IMAB)
- Previous Close
1.8100 - Open
1.8000 - Bid 1.2900 x 200
- Ask 2.3000 x 200
- Day's Range
1.7850 - 1.8288 - 52 Week Range
1.1600 - 3.4500 - Volume
137,423 - Avg. Volume
392,111 - Market Cap (intraday)
145.263M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-3.7200 - Earnings Date Mar 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.00
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
www.i-mabbiopharma.comRecent News: IMAB
Performance Overview: IMAB
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMAB
Valuation Measures
Market Cap
145.26M
Enterprise Value
-250.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.43
Enterprise Value/Revenue
0.99
Enterprise Value/EBITDA
0.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.11%
Return on Equity (ttm)
-62.02%
Revenue (ttm)
27.64M
Net Income Avi to Common (ttm)
-1.47B
Diluted EPS (ttm)
-3.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
2.28B
Total Debt/Equity (mrq)
4.36%
Levered Free Cash Flow (ttm)
--
Research Analysis: IMAB
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Research Reports: IMAB
Analyst Report: I-Mab
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
RatingBullishPrice TargetAnalyst Report: I-Mab
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
RatingBullishPrice TargetAnalyst Report: I-Mab
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
RatingBullishPrice TargetAnalyst Report: I-Mab
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
RatingBullishPrice Target